Literature DB >> 12922948

Treatment of severe proliferative lupus nephritis: the current state.

C C Mok1, R W S Wong, K N Lai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12922948      PMCID： PMC1754677          DOI： 10.1136/ard.62.9.799

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  79 in total

1.  Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study.

Authors:  B Pfueller; K Wolbart; A Bruns; G R Burmester; F Hiepe
Journal:  Arthritis Rheum       Date:  2001-08

2.  Treatment of systemic lupus erythematosus with LJP 394.

Authors:  R A Furie; J M Cash; M E Cronin; R S Katz; M H Weisman; C Aranow; M R Liebling; N P Hudson; C M Berner; S Coutts; H A de Haan
Journal:  J Rheumatol       Date:  2001-02       Impact factor: 4.666

3.  Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.

Authors:  C C Mok; C T Ho; Y P Siu; K W Chan; T H Kwan; C S Lau; R W Wong; T C Au
Journal:  Am J Kidney Dis       Date:  2001-08       Impact factor: 8.860

Review 4.  Advances in the treatment of lupus nephritis.

Authors:  R Zimmerman; J Radhakrishnan; A Valeri; G Appel
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

5.  Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.

Authors:  D I Daikh; D Wofsy
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

Review 6.  Cyclophosphamide for the treatment of systemic lupus erythematosus.

Authors:  K Takada; G G Illei; D T Boumpas
Journal:  Lupus       Date:  2001       Impact factor: 2.911

7.  Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

Authors:  J C Davis; M C Totoritis; J Rosenberg; T A Sklenar; D Wofsy
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

Review 8.  Severe lupus nephritis: importance of re-evaluating the histologic classification and the approach to patient care.

Authors:  E J Lewis; M M Schwartz; S M Korbet
Journal:  J Nephrol       Date:  2001 Jul-Aug       Impact factor: 3.902

9.  Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.

Authors:  C C Najafi; S M Korbet; E J Lewis; M M Schwartz; M Reichlin; J Evans
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

10.  Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.

Authors:  A E Traynor; J Schroeder; R M Rosa; D Cheng; J Stefka; S Mujais; S Baker; R K Burt
Journal:  Lancet       Date:  2000-08-26       Impact factor: 79.321
View more
  10 in total

1.  Semiquantitative and semi-automated morphometric evaluation of chronic lesions in renal biopsies.

Authors:  Daniel Abensur Athanazio; Gloria Maria Maranhão Sweet; Carlos Alberto Silva; Washington Luis Conrado dos-Santos
Journal:  Int Urol Nephrol       Date:  2008-11-07       Impact factor: 2.370

2.  Metabolic syndrome in systemic lupus erythematosus patients : Relationship to disease activity and neuropsychiatric lupus.

Authors:  N Hammam; S M Rashad; A A A Mohamed
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

3.  Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Effect on carotid intima-media thickness.

Authors:  T A Gheita; H A Raafat; S Sayed; H El-Fishawy; M M Nasrallah; E Abdel-Rasheed
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

4.  Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

Authors:  C Alejandro Arce-Salinas; Felipe Rodríguez-García; J Iván Gómez-Vargas
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

5.  Opposing Roles of Tyrosine Kinase Receptors Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated Nephritis.

Authors:  Yuxuan Zhen; Stephen O Priest; Wen-Hai Shao
Journal:  J Immunol       Date:  2016-08-15       Impact factor: 5.422

6.  Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona.

Authors:  Mehul P Dixit; Erika Bracamonte; Naznin Dixit
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

7.  Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.

Authors:  Amir Sharabi; Hava Azulai; Zev M Sthoeger; Edna Mozes
Journal:  Immunology       Date:  2007-03-07       Impact factor: 7.397

8.  Understanding lupus nephritis: diagnosis, management, and treatment options.

Authors:  Chi Chiu Mok
Journal:  Int J Womens Health       Date:  2012-05-22

9.  Improved prognostic diagnosis of systemic lupus erythematosus in an early stage of disease by a combination of different predictive biomarkers identified by proteome analysis.

Authors:  Maximilian Boenisch; Rebecca Hurst; Susanna Huber; Jadranka Koehn; Kurt Krapfenbauer
Journal:  EPMA J       Date:  2014-03-20       Impact factor: 6.543

10.  Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.

Authors:  Min Yang; Min Li; Wei He; Bin Wang; Yong Gu
Journal:  Exp Ther Med       Date:  2014-04-07       Impact factor: 2.447
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.